The interaction between pathogens and the host coagulation system

Physiology

Volumn 21, Issue 4, 2006, Pages 281-288

  Sun, Hongmin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PLASMINOGEN;

ANIMAL; BACTERIAL INFECTION; BLOOD CLOTTING; BLOODBORNE BACTERIUM; GENETIC VARIABILITY; GENETICS; HEMOSTASIS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOSIS;

ANIMALS; BACTERIAL INFECTIONS; BLOOD COAGULATION; BLOOD-BORNE PATHOGENS; FIBRINOGEN; HEMOSTASIS; HUMANS; PLASMINOGEN; THROMBOSIS; VARIATION (GENETICS);

EID: 33746619204     PISSN: 15489213     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiol.00059.2005     Document Type: Review

References (103)

1. Aird WC. Natural anticoagulant inhibitors: activated protein C. Best Pract Res Clin Haematol 17: 161-182, 2004.
2. Amaral A, Opal SM, and Vincent JL. Coagulation in sepsis. Intensive Care Med 30: 1032-1040, 2004.
3. Ben Nasr A, Wistedt A, Ringdahl U, and Sjobring U. Streptokinase activates plasminogen bound to human group C and G streptococci through M-like proteins. Eur J Biochem 222: 267-276, 1994.
4. Benfield TL, Dahl M, Nordestgaard BG, and Tybjaerg-Hansen A. Influence of the factor V leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 192: 1851-1857, 2005.
5. Berge A and Sjobring U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. J Biol Chem 268: 25417-25424, 1993.
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, and Fisher CJ Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
7. Beutler B. Sepsis begins at the interface of pathogen and host. Biochem Soc Trans 29: 853-859, 2001.
8. Boel G, Jin H, and Pancholi V. Inhibition of cell surface export of group A streptococcal anchorless surface dehydrogenase affects bacterial adherence and antiphagocytic properties. Infect Immun 73: 6237-6248, 2005.
9. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, Ziegler R, Bierhaus A, Martin E, and Nawroth PP. Role of NFkappaB in the mortality of sepsis. J Clin Invest 100: 972-985, 1997.
10. Boyle MD and Lottenberg R. Plasminogen activation by invasive human pathogens. Thromb Haemost 77: 1-10, 1997.
11. Broeseker TA, Boyle MD, and Lottenberg R. Characterization of the interaction of human plasmin with its specific receptor on a group A streptococcus. Microb Pathog 5: 19-27, 1988.
12. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 74: 90-93, 1995.
13. Broze GJ Jr. Tissue factor pathway inhibitor gene disruption. Blood Coagul Fibrinolysis 9, Suppl 1: S89-S92, 1998.
14. Chan WP, Lee CK, Kwong YL, Lam CK, and Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91: 1135-1139, 1998.
15. Christner R, Li Z, Raeder R, Podbielski A, and Boyle MD. Identification of key gene products required for acquisition of plasmin-like enzymatic activity by group A streptococci. J Infect Dis 175: 1115-1120, 1997.
16. Coleman JL and Benach JL. Use of the plasminogen activation system by microorganisms. J Lab Clin Med 134: 567-576, 1999.
17. Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH, and Benach JL. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 89: 1111-1119, 1997.
18. Coleman JL, Roemer EJ, and Benach JL. Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix. Infect Immun 67: 3929-3936, 1999.
19. Coleman JL, Sellati TJ, Testa JE, Kew RR, Furie MB, and Benach JL. Borrelia burgdorferi binds plasminogen, resulting in enhanced penetration of endothelial monolayers. Infect Immun 63: 2478-2484, 1995.
20. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 82: 259-270, 1999.
21. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, and Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91: 2850-2860, 1993.
22. D'Costa SS and Boyle MD. Interaction of group A streptococci with human plasmin(ogen) under physiological conditions. Methods 21: 165-177, 2000.
23. Dahlback B. Factor V and protein S as cofactors to activated protein C. Haematologica 82: 91-95, 1997.
24. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257: 209-223, 2005.
25. De SV, and Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica 80: 344-356, 1995.
26. DesJardin LE, Boyle MD, and Lottenberg R. Group A streptococci bind human plasmin but not other structurally related proteins. Thromb Res 55: 187-193, 1989.
27. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 114: 321-327, 2004.
28. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, and Kurosawa S. Inflammation, sepsis, and coagulation. Haematologica 84: 254-259, 1999.
29. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, and Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 84: 363-368, 1999.
30. Esmon CT and Mather T. Switching serine protease specificity. Nat Struct Biol 5: 933-937, 1998.
31. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, and Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 113: 1596-1606, 2004.
32. Franco RF and Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 109: 369-384, 2001.
33. Franco RF, Santos SE, Elion J, Tavella MH, and Zago MA. Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. Acta Haematol 100: 9-12, 1998.
34. Fuchs H, Simon MM, Wallich R, Bechtel M, and Kramer MD. Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes. Infect Immun 64: 4307-4312, 1996.
35. Fuchs H, Wallich R, Simon MM, and Kramer MD. The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor. Proc Natl Acad Sci USA 91: 12594-12598, 1994.
36. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, and Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 153: 3664-3672, 1994.
37. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, Flodgaard H, Lindbom L, and Bjorck L. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116: 367-379, 2004.
38. Ikebe T, Endoh M, and Watanabe H. Increased expression of the ska gene in emm49-genotyped Streptococcus pyogenes strains isolated from patients with severe invasive streptococcal infections. Jpn J Infect Dis 58: 272-275, 2005.
39. Iwanaga S, Kawabata S, and Muta T. New types of clotting factors and defense molecules found in horseshoe crab hemolymph: their structures and functions. J Biochem (Tokyo) 123: 1-15, 1998.
40. Iwanaga S, Miyata T, Tokunaga F, and Muta T. Molecular mechanism of hemolymph clotting system in Limulus. Thromb Res 68: 1-32, 1992.
41. Iwanaga S, Muta T, Shigenaga T, Miura Y, Seki N, Saito T, and Kawabata S. Role of hemocyte-derived granular components in invertebrate defense. Ann NY Acad Sci 712: 102-116, 1994.
42. Jagneaux T, Taylor DE, and Kantrow SP. Coagulation in sepsis. Am J Med Sci 328: 196-204, 2004.
43. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, and Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 160: 5130-5135, 1998.
44. Johnson LL, Berggren KN, Szaba FM, Chen W, and Smiley ST. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 197: 801-806, 2003.
45. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, and Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11199-11203, 2001.
46. Joyce DE and Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30: S288-S293, 2002.
47. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, and Dhainaut JF. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102: 3085-3092, 2003.
48. Korhonen TK, Lahteenmaki K, Kukkonen M, Pouttu R, Hynonen U, Savolainen K, Westerlund-Wikstrom B, and Virkola R. Plasminogen receptors. Turning Salmonella and Escherichia coli into proteolytic organisms. Adv Exp Med Biol 412: 185-192, 1997.
49. Kukkonen M, Saarela S, Lahteenmaki K, Hynonen U, Westerlund-Wikstrom B, Rhen M, and Korhonen TK. Identification of two laminin-binding fimbriae, the type 1 fimbria of Salmonella enterica serovar typhimurium and the G fimbria of Escherichia coli, as plasminogen receptors. Infect Immun 66: 4965-4970, 1998.
50. Lahteenmaki K, Kuusela P, and Korhonen TK. Plasminogen activation in degradation and penetration of extracellular matrices and basement membranes by invasive bacteria. Methods 21: 125-132, 2000.
51. Lahteenmaki K, Kuusela P, and Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 25: 531-552, 2001.
52. Lahteenmaki K, Virkola R, Pouttu R, Kuusela P, Kukkonen M, and Korhonen TK. Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infect Immun 63: 3659-3664, 1995.
53. Lahteenmaki K, Westerlund B, Kuusela P, and Korhonen TK. Immobilization of plasminogen on Escherichia coli flagella. FEMS Microbiol Lett 106: 309-314, 1993.
54. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 16: 167-177, 2001.
55. Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, and Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 101: 4823-4827, 2003.
56. Levi M, Keller TT, van Gorp E, and ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 60: 26-39, 2003.
57. Levi M, ten Cate H, and van der PT. Endothelium: interface between coagulation and inflammation. Crit Care Med 30: S220-S224, 2002.
58. Levi M, van der PT, and Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704, 2004.
59. Li Z, Ploplis VA, French EL, and Boyle MD. Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model. J Infect Dis 179: 907-914, 1999.
60. Lijnen HR and Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost 74: 387-390, 1995.
61. Lottenberg R, Broder CC, and Boyle MD. Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 55: 1914-1918, 1987.
62. Lottenberg R, DesJardin LE, Wang H, and Boyle MD. Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity. J Infect Dis 166: 436-440, 1992.
63. Marcum JA and Kline DL. Species specificity of streptokinase. Comp Biochem Physiol B 75: 389-394, 1983.
64. McCoy HE, Broder CC, and Lottenberg R. Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation. J Infect Dis 164: 515-521, 1991.
65. McDonough KA, Barnes AM, Quan TJ, Montenieri J, and Falkow S. Mutation in the pla gene of Yersinia pestis alters the course of the plague bacillus-flea (Siphonaptera:Ceratophyllidae) interaction. J Med Entomol 30: 772-780, 1993.
66. McDonough KA and Falkow S. A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and fibrinolysin-associated phenotypes. Mol Microbiol 3: 767-775, 1989.
67. McKay FC, McArthur JD, Sanderson-Smith ML, Gardam S, Currie BJ, Sriprakash KS, Fagan PK, Towers RJ, Batzloff MR, Chhatwal GS, Ranson M, and Walker MJ. Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect Immun 72: 364-370, 2004.
68. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, and Topol EJ. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol 31: 1493-1498, 1998.
69. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, and Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol Lung Cell Mol Physiol 272: L197-L202, 1997.
70. Muta T and Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 8: 41-47, 1996.
71. Nakamura S, Takagi T, Iwanaga S, Niwa M, and Takahashi K. Amino acid sequence studies on the fragments produced from horseshoe crab coagulogen during gel formation: homologies with primate fibrinopeptide B. Biochem Biophys Res Commun 72: 902-908, 1976.
72. Nowicki ST, Minning-Wenz D, Johnston KH, and Lottenberg R. Characterization of a novel streptokinase produced by Streptococcus equisimilis of nonhuman origin. Thromb Haemost 72: 595-603, 1994.
73. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9, Suppl 1: S9-S14, 1998.
74. Pancholi V and Fischetti VA. Alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 273: 14503-14515, 1998.
75. Parkkinen J, Hacker J, and Korhonen TK. Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by Escherichia coli S fimbriae associated with neonatal septicaemia and meningitis. Thromb Haemost 65: 483-486, 1991.
76. Pawar A, Ghosh K, Shetty S, Colah R, and Mohanty D. High frequency of factor V Leiden mutation in Parsis: a highly endogamous population in India. Thromb Haemost 83: 965, 2000.
77. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, and Mackman N. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 103: 1342-1347, 2004.
78. Price DT and Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 127: 895-903, 1997.
79. Price GC, Thompson SA, and Kam PC. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 59: 483-492, 2004.
80. Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, and Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol 36: 386-389, 2004.
81. Ringdahl U and Sjobring U. Analysis of plasminogen-binding M proteins of Streptococcus pyogenes. Methods 21: 143-150, 2000.
82. Ringdahl U, Svensson HG, Kotarsky H, Gustafsson M, Weineisen M, and Sjobring U. A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. Mol Microbiol 37: 1318-1326, 2000.
83. Ringdahl U, Svensson M, Wistedt AC, Renne T, Kellner R, Muller-Esterl W, and Sjobring U. Molecular co-operation between protein PAM and streptokinase for plasmin acquisition by Streptococcus pyogenes. J Biol Chem 273: 6424-6430, 1998.
84. Roemisch J, Gray E, Hoffmann JN, and Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 13: 657-670, 2002.
85. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, Hedman H, and Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 153: 3245-3255, 1994.
86. Schroeder B, Boyle MD, Sheerin BR, Asbury AC, and Lottenberg R. Species specificity of plasminogen activation and acquisition of surface-associated proteolytic activity by group C streptococci grown in plasma. Infect Immun 67: 6487-6495, 1999.
87. Sjostrom I, Grondahl H, Falk G, Kronvall G, and Ullberg M. Purification and characterisation of a plasminogen-binding protein from Haemophilus influenzae. Sequence determination reveals identity with aspartase. Biochim Biophys Acta 1324: 182-190, 1997.
88. Sodeinde OA and Goguen JD. Genetic analysis of the 9.5-kilobase virulence plasmid of Yersinia pestis. Infect Immun 56: 2743-2748, 1988.
89. Sodeinde OA and Goguen JD. Nucleotide sequence of the plasminogen activator gene of Yersinia pestis: relationship to ompT of Escherichia coli and gene E of Salmonella typhimurium. Infect Immun 57: 1517-1523, 1989.
90. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, and Goguen JD. A surface protease and the invasive character of plague. Science 258: 1004-1007, 1992.
91. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjobring U, and Ginsburg D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305: 1283-1286, 2004.
92. Taylor FB Jr, Chang A, Hinshaw LB, Esmon CT, Archer LT, and Beller BK. A model for thrombin protection against endotoxin. Thromb Res 36: 177-185, 1984.
93. Tillett WS and Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 58: 485-502, 1933.
94. Ullberg M, Kuusela P, Kristiansen BE, and Kronvall G. Binding of plasminogen to Neisseria meningitidis and Neisseria gonorrhoeae and formation of surface-associated plasmin. J Infect Dis 166: 1329-1334, 1992.
95. Wang H, Lottenberg R, and Boyle MD. A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. J Infect Dis 171: 85-92, 1995.
96. Wang H, Lottenberg R, and Boyle MD. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb Pathog 18: 153-166, 1995.
97. Wang S, Reed GL, and Hedstrom L. Zymogen activation in the streptokinase-plasminogen complex. Ile1 is required for the formation of a functional active site. Eur J Biochem 267: 3994-4001, 2000.
98. Weiler H, Kerlin B, and Lytle MC. Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 32: S233-S238, 2004.
99. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, and Weitz JI. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 21: 1531-1537, 2001.
100. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, and Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110: 130-134, 2000.
101. Winram SB and Lottenberg R. The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Microbiology 142: 2311-2320, 1996.
102. Wistedt AC, Ringdahl U, Muller-Esterl W, and Sjobring U. Identification of a plasminogen-binding motif in PAM, a bacterial surface protein. Mol Microbiol 18: 569-578, 1995.
103. Yuksel M, Okajima K, Uchiba M, Horiuchi S, and Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 88: 267-273, 2002.